Gut microbiome-shaped chemotherapy responses across cancer types: mechanisms of resistance, biomarkers, and targeted interventions
- 1Department of Gynecology, Affiliated Hospital of Chifeng University
- 2Department of Urology, Affiliated Hospital of Chifeng University
- 3General Office, Affiliated Hospital of Chifeng University
Abstract
Cytotoxic chemotherapy remains an important component of multimodal treatment for many solid tumors, but resistance and dose-limiting toxicities continue to constrain clinical benefit. The gut microbiome can influence chemotherapy response through microbial drug biotransformation, metabolite signaling, intestinal-barrier integrity, systemic immune regulation, and tumor-cell stress and death pathways. Across solid tumors, the evidence is strongest in colorectal cancer, where clinical associations are supported by increasingly detailed mechanistic and interventional studies; evidence in many extraintestinal cancers remains less mature and is dominated by smaller observational cohorts and selected preclinical models. Importantly, gut-derived systemic effects should be distinguished from local or tumor-associated microbial mechanisms, and direct tumor-cell resistance should be separated from altered drug exposure and toxicity-mediated reductions in relative dose intensity. Microbiota-associated and metabolic biomarkers and microbiota-targeted interventions show potential for treatment stratification, toxicity prediction, and therapeutic modulation, but clinical translation remains limited by heterogeneous cohorts, incomplete causal validation, variable engraftment and strain specificity, and safety and standardization requirements. Overall, the microbiome is best viewed as a cancer- and regimen-specific modifier of chemotherapy rather than a universal determinant of response. Prospective, mechanism-matched studies are needed to establish whether microbiome-guided strategies can improve treatment efficacy, tolerance, and completion.
Related
- Nutritional Modulation of the Microbiota–Gut–Brain Axis in Cancer-Related Fatigue: A Narrative Review of Mechanisms, Biomarkers, and Interventions
- The microbiome-metabolome axis in colorectal cancer therapy resistance: mechanisms, mediators, and therapeutic opportunities
- Gut Microbiome Compositional and Functional Signatures Associated with Chemotherapy Response in Pancreatic Ductal Adenocarcinoma: An Exploratory Cohort Study.
- Microbiome-driven precision psychiatry: integrating multi-omics, artificial intelligence, and personalized interventions along the gut-brain axis
- The gastric ecosystem: assessing resident microbiome vs. transient microorganisms in obesity and following bariatric interventions
BibTeX
@article{shao2026microbiomeshaped,
title = {{Gut microbiome-shaped chemotherapy responses across cancer types: mechanisms of resistance, biomarkers, and targeted interventions}},
author = {Ting Shao and Minghui Li and Shaolin Li and Jie Pu and Chunsheng Li and Changgang Guo},
journal = {Frontiers in Immunology},
year = {2026},
month = oct,
doi = {10.3389/fimmu.2026.1945287},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1945287/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Gut microbiome-shaped chemotherapy responses across cancer types: mechanisms of resistance, biomarkers, and targeted interventions
AU - Ting Shao
AU - Minghui Li
AU - Shaolin Li
AU - Jie Pu
AU - Chunsheng Li
AU - Changgang Guo
PY - 2026
DA - 2026/10/05
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1945287
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1945287/full
AB - Cytotoxic chemotherapy remains an important component of multimodal treatment for many solid tumors, but resistance and dose-limiting toxicities continue to constrain clinical benefit. The gut microbiome can influence chemotherapy response through microbial drug biotransformation, metabolite signaling, intestinal-barrier integrity, systemic immune regulation, and tumor-cell stress and death pathways. Across solid tumors, the evidence is strongest in colorectal cancer, where clinical associations are supported by increasingly detailed mechanistic and interventional studies; evidence in many extraintestinal cancers remains less mature and is dominated by smaller observational cohorts and selected preclinical models. Importantly, gut-derived systemic effects should be distinguished from local or tumor-associated microbial mechanisms, and direct tumor-cell resistance should be separated from altered drug exposure and toxicity-mediated reductions in relative dose intensity. Microbiota-associated and metabolic biomarkers and microbiota-targeted interventions show potential for treatment stratification, toxicity prediction, and therapeutic modulation, but clinical translation remains limited by heterogeneous cohorts, incomplete causal validation, variable engraftment and strain specificity, and safety and standardization requirements. Overall, the microbiome is best viewed as a cancer- and regimen-specific modifier of chemotherapy rather than a universal determinant of response. Prospective, mechanism-matched studies are needed to establish whether microbiome-guided strategies can improve treatment efficacy, tolerance, and completion.
SN - 1664-3224
ER -